SARS-CoV-2 is an emerging virus causing the contemporary global pandemic. No cure has yet been discovered. Therefore, vaccination remains the only hope. We report the case of a 66-year-old male patient with a history of allergies. Five hours after his vaccination with the anti-COVID-19 vaccine AZD1222 (ChAdOx1 nCoV-19, AstraZeneca), he developed acute respiratory distress. The biological assessment showed hyperleukocytosis, 20% of which are eosinophils. Diagnosis of severe postvaccination acute eosinophilic pneumonia was retained given the history of allergy, lack of improvement on antibiotics, elimination of all other probable causes of eosinophilia, and improvement on corticosteroids. Such reactions of eosinophilic pneumonia have only been described twice: once following vaccination with the influenza vaccine (Vaxigrip*) and the other after vaccination with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23*). Hypereosinophilia must be taken into consideration, feared, and prevented. Although rare and severe, post-COVID-19 vaccination acute eosinophilic pneumonia remains well manageable with corticosteroids with a good outcome. Therefore, in some poorly monitored patients with allergy or asthma, the use of another less allergenic vaccine could be considered to avoid such reactions.

Objective: To date, the vaccine is the only weapon to stop the global pandemic caused by the SARS-CoV-2. But, several clinical cases of complications have been reported in the literature especially allergic reactions. Case report: We report a case of 35-year-old woman, known asthmatic with history of a chronic urticaria, an allergic rhinoconjunctivitis and an angioedema after taking NSAIDs. The patient presented 10 minutes after vaccination by Pfizer-BioNTech vaccine, an immediate allergic reaction complicated 12 hours after, by an angioedema. Discussion: During the first wave of COVID-19, and after initiation of the vaccination program in Morocco, vaccinating people with severe allergies was not recommended. This reality was changed after the second wave of SARS-CoV-2 Delta, on condition of doing it under medical monitoring. We should propose to all risky persons to take a premedication if needed to avoid such reactions considering the benefits incurred. The use of anti-histamines seems to be necessary. But as in our patient’s case, anti-histamines alone were not sufficient to avoid this local reaction. They probably reduced the intensity of the reaction but did not avoid it. Therefore, we should propose a combination of drugs made by corticosteroids and anti-histamines as a premedication may be a safe alternative to the risky patients and last but not least a close monitoring should be proposed. Conclusion: The main purpose of this case if to raise awareness of this side effect among practitioners and make them capable to managing it correctly.

No abstract

An ischemic stroke is characterized by the brutal installation of a focal functional deficit. Myxomas are the most common primitive cardiac tumors. Neurological manifestations of myxomas are mostly related to cardioembolic events, either caused by a migrating fragment of the tumor or by an attached clot that got detached from the tumor This article describes the case of a 55-year-old male who presented with an ischemic stroke of the vertebrobasilar territory. Cardiac exploration revealed the presence of a cardiac mass. The patient was surgically treated and the anatomopathological study confirmed the diagnosis of cardiac myxoma. This case emphasizes the obligation to research the etiology of ischemic strokes, and more importantly the realization of a complete cardiologic exploration.

Introduction: The SARS-CoV-2 made the world stop its activities, and the only chance of returning to normal life is the vaccine. But like any vaccination, some complications have been reported. We report the case of a patient who presented a myositis following the administration of the Covishield* (AZD1222, ChAdOx1 nCoV-19, AstraZeneca) Covid-19 vaccine. Case Report: 12 hours after his first dose, an 84-year-old patient presented to us reporting a decreased muscle strength: the patient can move against gravity but not against resistance. The biological assessment showed that CK was at 4,250 IU/L, myoglobin was at 144 microgram/L and aldolases at 16.9 U/L. The patient received high doses of corticosteroids. Discussion: The development of vaccines and immunization programs reduced the morbidity and mortality of several diseases. Other case reports suggested the possible association between myopathies and the administration of the hepatitis B vaccine and H1N1 plus the seasonal trivalent influenza and other vaccines. The exact mechanism is still unknown, but a presumable autoimmune phenomenon is incriminated. Conclusion: The main purpose of this case report is to raise awareness about the possible link between the Covid-19 vaccination and polymyositis and the urge to take charge to avoid further complications.